BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics (BALance)
Check the BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics Profiling and Radiomics
Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema. Pathomechanisms include barrier breakdown, immunopathology, haemostatic derailment and dysbiosis; however, the actual sequence of events and how they cumulatively lead to lung failure remains unclear. Although ARDS is frequently triggered by pneumonia, it can also occur as a result of trauma, aspiration or non-pulmonary causes. Importantly, ARDS is highly heterogeneous; growing evidence points to aetiology-specific pathomechanisms - a circumstance that explains why attempts to develop specific drugs or timely diagnostic markers have so far failed.
A comprehensive analysis of key microenvironmental and haemostasis-related parameters of the lung, combined with multidimensional quantitative image features derived from chest CT scans (radiomics), will enable us to i) identify ARDS phenotypes with different biological characteristics and ii) generate new hypotheses regarding aetiology- or subgroup-specific mechanisms, molecular markers and therapeutic options.
Our approach is based on ICU management of our patients guided by bronchoalveolar lavage fluid (BALF). Together with previously sampled cases and new samples collected as part of this study, our cohort will consist of patients with i) COVID-19-associated ARDS, ii) ARDS associated with other viral pneumonia, iii) ARDS associated with bacterial pneumonia, and iv) ARDS of non-pulmonary origin. Bacterial and fungal co-infections and superinfections are recorded in all patients and taken into account in the stratification. Patients with pneumonia without ARDS, as well as ventilated patients without underlying lung disease, serve as controls. To characterise the microbial lung microenvironment, the investigators combine data from routine microbiological diagnostics with microbiome sequencing and metabolomics. In addition, the investigators conduct comprehensive and longitudinal immune and haemostatic profiling by regularly analysing immune cells, cytokines and parameters of immune thrombosis in BALF and blood. Multi-omics integration then identifies phenotypic subgroups by merging all multimodal datasets - including radiomics. Selected samples from identified clusters are then further characterised using single-cell sequencing to uncover specific features/markers and pathomechanisms of the respective ARDS subtypes.
Although it is clear that the pathogenesis of ARDS is multifactorial, comprehensive studies that integrate all relevant parameters are rare. Radiomics is increasingly recognised as a powerful tool for capturing the clinical status of ARDS in detail; however, to date, this imaging data has not been systematically linked to other omics readouts. The investigators aim to bridging this gap by conducting a thorough investigation across various ARDS aetiologies in the present study, incorporating all identifiable key factors.
Our interdisciplinary team comprises basic immunologists, infectious disease and computational biologists, as well as clinicians with expertise in ARDS, infectious diseases, immunothrombosis and radiology.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Oliver Robak, Prof. PD Dr.
- Numero di telefono: +43 1 40400 44920
- Email: oliver.robak@meduniwien.ac.at
Backup dei contatti dello studio
- Nome: Riem Gawish, PhD
- Numero di telefono: +43 1 40400 51480
- Email: riem.gawish@meduniwien.ac.at
Luoghi di studio
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, 1090
- General Hospital of Vienna, Medical University of Vienna
-
Contatto:
- Oliver Robak, Ap. Prof. Priv.-Doz. Dr.
- Numero di telefono: +43 1 40400 44920
- Email: oliver.robak@meduniwien.ac.at
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- male and female
- aged 18 years or over
- signed consent form
- depending on the study group: Confirmed ARDS according to the Berlin criteria (see below, Groups B and D) Confirmed severe CAP requiring mechanical ventilation and intensive care (see below, Groups B and C) Ventilated patients without signs of ARDS (see below, Group E)
Exclusion Criteria:
- under 18 years of age
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
COVID-19 ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Altri nomi:
|
|
Pneumonia-induced ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Altri nomi:
|
|
Severe pneumonia but no ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Altri nomi:
|
|
Non-pulmonary origin ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Altri nomi:
|
|
No lung pathology
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
ARDS phenotypes
Lasso di tempo: 4 years
|
The application of multi-omics cluster analysis to reveal any distinct ARDS phenotypes or subgroup-specific characteristics.
|
4 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Lung Microbiome Composition Analysis via 16S rRNA Gene Sequencing of Bronchoalveolar Lavage (BAL) Fluid
Lasso di tempo: 4 years
|
Differences in the microbial community composition (alpha diversity, beta diversity, and taxonomic abundance at phylum/genus level) of the lower respiratory tract microbiome in intensive care patients with ARDS
|
4 years
|
|
Metabolomic Profile of Bronchoalveolar Lavage Fluid and Plasma
Lasso di tempo: 4 years
|
Differences in the metabolomic profile (relative concentrations of annotated metabolites and pathway-level scores) in bronchoalveolar lavage (BAL) fluid and plasma between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection).
Metabolomic measurements will be performed using the METAB02, AMINO01, and LIPID01 or other appropriate packages.
Samples will be analyzed via mass spectrometry to quantify a wide range of analytes, including various amino acids, lipids and their subclasses, and metabolites such as pyruvate, lactate, citrate, and succinate.
|
4 years
|
|
Inflammatory Cytokine Profile in Bronchoalveolar Lavage Fluid and Plasma
Lasso di tempo: 4 years
|
Concentrations of predefined pro- and anti-inflammatory cytokines (e.g., IL-6, IL-8, TNF-α, others according to panel) in BAL fluid and plasma of ARDS patients, and detection of differences between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection) by Multiplex bead-based immunoassay or ELISA panels (e.g., Luminex, electrochemiluminescence).
|
4 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Oliver Robak, Prof. PD Dr., Medical University of Vienna, Department of Medicine 1
- Investigatore principale: Riem Gawish, PhD, Medical University of Vienna, Department of Medicine 1
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni delle vie respiratorie
- Infezioni
- Infezioni da Orthomyxoviridae
- Infezioni da virus a RNA
- Malattie virali
- Malattie delle vie respiratorie
- Malattie polmonari
- Polmonite, virale
- Infezioni da coronavirus
- Infezioni da Coronaviridae
- Infezioni da Nidovirus
- Lesione polmonare
- COVID-19
- Influenza, umana
- Polmonite
- Lesioni polmonari acute
- Coinfezione
- Tecniche investigative
- Terapie
- Paracentesi
- Gestione dei campioni
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Forature
- Procedure chirurgiche, operative
- Collezione di campioni di sangue
- Cordocentesi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2405/2025
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su ARDS (sindrome da distress respiratorio acuto)
-
NCT07567768Non ancora reclutamentoARDS (sindrome da distress respiratorio acuto)
-
NCT07380373Iscrizione su invitoARDS (sindrome da distress respiratorio acuto)
-
NCT07231107CompletatoARDS (sindrome da distress respiratorio acuto)
-
NCT07623590ReclutamentoARDS (sindrome da distress respiratorio acuto)
-
NCT07617298Non ancora reclutamentoARDS (sindrome da distress respiratorio acuto)
-
NCT07309783Non ancora reclutamentoARDS (sindrome da distress respiratorio acuto)
-
NCT07328997CompletatoARDS (sindrome da distress respiratorio acuto) | IA (Intelligenza Artificiale)
-
NCT07342205ReclutamentoSindrome da distress respiratorio acuto (ARDS) | Lesioni polmonari acute (ALI) | Lesione Polmonare Acuta/Sindrome da Distress Respiratorio Acuto Correlata alla Sepsi
-
NCT07449572ReclutamentoARDS (sindrome da distress respiratorio acuto)
-
NCT07327268Non ancora reclutamentoARDS (sindrome da distress respiratorio acuto) | Tomografia ad impedenza elettrica (EIT) | Perfusione Polmonare
Prove cliniche su sampling blood
-
NCT07163338Reclutamento
-
NCT06880406Reclutamento
-
NCT03871452CompletatoDisturbo della coagulazione
-
NCT05390424ReclutamentoEpatite B | Epatite C | AIDS
-
NCT00814151CompletatoSepsi | Batteriemia | Infezione | Infezione da stafilococco
-
NCT04315727ReclutamentoPredisposizione genetica alla malattia | Malattie Rare
-
NCT02676245Completato
-
NCT06854419Completato
-
NCT02295501Terminato